Gifted Molecular Science
Biotechnology startup developing a fourth-generation antisense oligonucleotide (ASO) platform based on modified peptide nucleic acids (PNA). The company focuses on antiviral therapeutics by designing cell-permeable ASOs that directly target viral genomes, with programs in SARS‑CoV‑2, flaviviruses, CNS genetic disorders, and a dPNA-based material for nucleic acid purification. Activities include discovery, preclinical development, GLP contracting, manufacturing outsourcing, IP filings and scientific publications.
Industries
N/A
Products
Platform-derived antiviral ASO candidate (SARS‑CoV‑2)
A cell-permeable ASO candidate discovered using the modified PNA platform that targets conserved regions of SARS‑CoV‑2 and showed in vitro inhibition of viral replication with IC50 potency reported as superior to a comparator antiviral.
dPNA-based RNA affinity material
Modified PNA material optimized for nucleic acid separation and purification (RNA affinity column application).
Platform-derived antiviral ASO candidate (SARS‑CoV‑2)
A cell-permeable ASO candidate discovered using the modified PNA platform that targets conserved regions of SARS‑CoV‑2 and showed in vitro inhibition of viral replication with IC50 potency reported as superior to a comparator antiviral.
dPNA-based RNA affinity material
Modified PNA material optimized for nucleic acid separation and purification (RNA affinity column application).
Services
Research collaborations and technology licensing
Collaborative R&D and technology transfer engagements with academic and industry partners; participation in partnering events and accelerator programs.
Manufacturing and GLP contracting
Provision or management of outsourced manufacturing and GLP nonclinical study contracts to support development programs.
Research collaborations and technology licensing
Collaborative R&D and technology transfer engagements with academic and industry partners; participation in partnering events and accelerator programs.
Manufacturing and GLP contracting
Provision or management of outsourced manufacturing and GLP nonclinical study contracts to support development programs.
Expertise Areas
- Antisense oligonucleotide design
- Peptide nucleic acid chemistry
- Antiviral drug discovery
- Preclinical development and GLP study coordination
Key Technologies
- Peptide nucleic acids (PNA)
- Cationic-lipid chemical modification of oligonucleotides
- Antisense oligonucleotides (ASO)
- Cell-based antiviral assays (Vero6 model)